Advances in the macrolides and quinolones.
The widespread, frequent clinical use of the macrolides and quinolones has led to resistance in several species. With the prevailing increase of resistance, new developmental compounds with improved spectra, pharmacokinetics, and reduced adverse effects are required, coupled with logical use of the current armamentarium.
Boswell
F J
FJ
Department of Medical Microbiology, City Hospital NHS Trust, Birmingham, United Kingdom.
Wise
R
R
D042462:4-Quinolones; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000737:chemistry / Q000494:pharmacology*; D001441:Bacteroides fragilis / Q000187:drug effects; D016993:Chlamydophila pneumoniae / Q000187:drug effects; D004250:DNA Topoisomerases, Type II / Q000187:drug effects; D004352:Drug Resistance, Microbial / Q000502:physiology; D005798:Genes, Bacterial / Q000502:physiology; D016946:Gram-Negative Aerobic Rods and Cocci / Q000187:drug effects / Q000235:genetics; D006095:Gram-Positive Cocci / Q000187:drug effects / Q000235:genetics; D006193:Haemophilus influenzae / Q000187:drug effects; D016952:Legionella pneumophila / Q000187:drug effects; D018942:Macrolides; D009154:Mutation / Q000187:drug effects; D009177:Mycoplasma pneumoniae / Q000187:drug effects; D013329:Structure-Activity Relationship
D042462:4-Quinolones; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D018942:Macrolides; D004250:DNA Topoisomerases, Type II